Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Investigation of Dextromethorphan-Bupropion on Affective and Cognitive Processing: A Mechanistic Pilot fMRI Clinical Study

EF 2025-26

Résumé
Major Depressive Disorder (MDD) is a leading contributor to disability and reduction in health-related quality of life. Anhedonia, defined as a reduced capacity to anticipate or experience pleasure, is one of the core symptoms of MDD and is associated with increased suicide risk and long-term functional impairment. Anhedonia is further linked to deficits in reward learning, effort-based decision-making, and cognitive regulation, which are proposed to arise from disruptions in corticostriatal circuitry (e.g., striatum and prefrontal regions). Conventional monoaminergic antidepressants often remain insufficient in remediating these cognitive and motivational disturbances. Consequently, individuals may continue to experience residual symptoms that impair daily functioning, which highlights the need for novel therapeutics that target neural mechanisms underlying depression. Dextromethorphan/Bupropion (DEX/BUP) was recently approved (2022) as a novel rapid-acting antidepressant that engages glutamatergic and monoaminergic pathways for the treatment of adults with MDD. Current clinical trials demonstrate both rapid and clinically meaningful improvements in depressive symptoms, including anhedonia and cognitive functioning. However, the mechanisms underlying these effects remain insufficiently understood. This study will use functional magnetic resonance imaging and the Effort Expenditure for Rewards Task to investigate how DEX/BUP influences striatal and prefrontal activity during reward-guided task in adults with MDD. By clarifying associated neural mechanisms, this pilot trial aims to advance the development of more precise, mechanism-based interventions that can improve motivation, cognitive functioning, and daily functioning for individuals living with MDD.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573340
Name
Zheng Yang Jing
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigation of Dextromethorphan-Bupropion on Affective and Cognitive Processing: A Mechanistic Pilot fMRI Clinical Study
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Affective Processing; Antidepressant; Cognitive Processing; Depression; Dextromethorphan-Buproprion; Fmri; Major Depressive Disorder; Mechanistic; Mood Disorder; Neuroimaging
Abstract
Major Depressive Disorder (MDD) is a leading contributor to disability and reduction in health-related quality of life. Anhedonia, defined as a reduced capacity to anticipate or experience pleasure, is one of the core symptoms of MDD and is associated with increased suicide risk and long-term functional impairment. Anhedonia is further linked to deficits in reward learning, effort-based decision-making, and cognitive regulation, which are proposed to arise from disruptions in corticostriatal circuitry (e.g., striatum and prefrontal regions). Conventional monoaminergic antidepressants often remain insufficient in remediating these cognitive and motivational disturbances. Consequently, individuals may continue to experience residual symptoms that impair daily functioning, which highlights the need for novel therapeutics that target neural mechanisms underlying depression. Dextromethorphan/Bupropion (DEX/BUP) was recently approved (2022) as a novel rapid-acting antidepressant that engages glutamatergic and monoaminergic pathways for the treatment of adults with MDD. Current clinical trials demonstrate both rapid and clinically meaningful improvements in depressive symptoms, including anhedonia and cognitive functioning. However, the mechanisms underlying these effects remain insufficiently understood. This study will use functional magnetic resonance imaging and the Effort Expenditure for Rewards Task to investigate how DEX/BUP influences striatal and prefrontal activity during reward-guided task in adults with MDD. By clarifying associated neural mechanisms, this pilot trial aims to advance the development of more precise, mechanism-based interventions that can improve motivation, cognitive functioning, and daily functioning for individuals living with MDD.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zheng, Yang Jing
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~